Delcath Systems, Inc. (DCTH) Stock

Delcath Systems, Inc., an interventional oncology company based in New York, New York, is dedicated to advancing treatments for primary and metastatic liver cancers across the United States and Europe. At the forefront of its portfolio is HEPZATO KIT, a specialized system designed for the hepatic delivery of melphalan hydrochloride. This innovative approach allows for targeted, high-dose chemotherapy directly to the liver while minimizing systemic exposure and associated side effects. The company's commitment to precision medicine is underscored by ongoing clinical development efforts, such as the FOCUS trial, which aims to evaluate the objective response rate in patients with hepatic dominant ocular melanoma.

Delcath Systems also offers the HEPZATO system as a standalone medical device known as the CHEMOSAT Hepatic Delivery System for Melphalan. This platform is available in medical centers throughout Europe, providing clinicians with a comprehensive tool to treat various liver cancers effectively. The company continues to expand its therapeutic capabilities and geographic reach, leveraging decades of expertise in interventional oncology to address critical unmet needs in liver cancer treatment.

Established in 1988, Delcath Systems has maintained its headquarters in New York City, where it has built a reputation for innovation and clinical excellence in the field of oncology. With a steadfast focus on enhancing patient outcomes through targeted therapies and advanced delivery systems, Delcath Systems remains committed to pioneering new standards of care in the fight against liver cancers worldwide.